•  
• Tweet
•  
•  
•        Print
•  
•        Email
•  
•         Track Keywords

This is the third new CLO priced globally by CVC Credit in 2025, which combined have an aggregate value of c.$1.4bn (c.€1.3bn). Apidos LIII has a five-year reinvestment period and two-year non-call period, backed by a diversified portfolio of senior secured assets.

Cary Ho, Partner and Global Head of CLO origination at CVC Credit, said: "Apidos LIII was very well received from our global investors during very challenging market conditions, which reflects CVC's proven track record, and the strength of our relationships with global investors across the capital stack. We are happy with the structure and the quality of assets we have been able to purchase during the early stages of this deal." 

Kevin O'Meara, Partner and Global Co-Head of Performing Credit at CVC Credit, added: "Our team's activity has remained robust over the past four months, even against the backdrop of increased volatility across financial markets. Since the inception of our business in 2005, our growing and loyal investor base has entrusted us with delivering stable and consistent performance throughout cycles. We believe the volatility over the last couple of months has and will continue to create attractive investment options for our investors and we will strive to capitalize on these opportunities."